In a report released yesterday, Patrick Walravens from JMP Securities maintained a Buy rating on Global-e Online (GLBE – Research Report), with a price target of $41.00. The company’s shares closed last Tuesday at $19.78, close to its 52-week low of $15.63.
According to TipRanks.com, Walravens is a 4-star analyst with an average return of 4.1% and a 44.4% success rate. Walravens covers the Technology sector, focusing on stocks such as Zoom Video Communications, Qualtrics International, and ZoomInfo Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global-e Online with a $32.33 average price target, representing a 71.4% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $25.00 price target.
The company has a one-year high of $83.77 and a one-year low of $15.63. Currently, Global-e Online has an average volume of 1.89M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global E Online Ltd provides e-commerce solutions. It offers a platform to enable and accelerate global, direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from, and to, anywhere in the world. It localizes the shopper experience in an effort to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce.
Read More on GLBE:
- JMP Securities Thinks Vor Biopharma’s Stock is Going to Recover
- JMP Securities Keeps a Buy Rating on Taysha Gene Therapies (TSHA)
- JMP Securities Maintains a Buy Rating on Cellectis SA (CLLS)
- Healthcare Realty (HR) Receives a Hold from BMO Capital
- Analysts Are Bullish on Top Healthcare Stocks: Enanta Pharmaceuticals (ENTA), MacroGenics (MGNX)